Last reviewed · How we verify
Amoxicillin during SRP
Amoxicillin during SRP is a Penicillin antibiotic Small molecule drug developed by Belén Retamal-Valdes. It is currently in Phase 1 development for Bacterial infections.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Amoxicillin during SRP |
|---|---|
| Sponsor | Belén Retamal-Valdes |
| Drug class | Penicillin antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that works by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death.
Approved indications
- Bacterial infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Allergic reactions
Key clinical trials
- Amoxicillin and Metronidazole During or After the Periodontal Treatment (NA)
- Amoxicillin and Metronidazole During Periodontal Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin during SRP CI brief — competitive landscape report
- Amoxicillin during SRP updates RSS · CI watch RSS
- Belén Retamal-Valdes portfolio CI
Frequently asked questions about Amoxicillin during SRP
What is Amoxicillin during SRP?
How does Amoxicillin during SRP work?
What is Amoxicillin during SRP used for?
Who makes Amoxicillin during SRP?
What drug class is Amoxicillin during SRP in?
What development phase is Amoxicillin during SRP in?
What are the side effects of Amoxicillin during SRP?
What does Amoxicillin during SRP target?
Related
- Drug class: All Penicillin antibiotic drugs
- Target: All drugs targeting Penicillin-binding proteins
- Manufacturer: Belén Retamal-Valdes — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing